CHMP fandt, at vurderingen gav anledning til betænkelighed vedrørende risk/ benefit forholdet for piroxicam, og underrettede Europa- Kommissionen herom.
The CHMP considered that the assessment raised concerns on the benefit/ risk balance of piroxicam and informed the European Commission accordingly.